Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
3 pending office actions • 3 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Samsung Electronics has 3 pending office actions within the Biotechnology & Pharmaceuticals technology area. These matters are distributed across 3 distinct examiners and 3 distinct art units. This level of dispersion indicates that each active case is being evaluated independently by different technical personnel.
The busiest examiner, PATTERSON, SARAH COOPER, is responsible for 1 pending office action. Since there are 3 pending office actions in total, the workload is spread among the 3 distinct examiners. The involvement of 3 distinct art units reflects the varied technical scope of the company's current pharmaceutical applications.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 2 (67%) |
| Multi-statute (no §101) | 1 (33%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| PATTERSON, SARAH COOPER | 1 | 55.3% | +59.5% |
| ALSOMAIRY, SARAH ABDOALATIF | 1 | 57.8% | +30.2% |
| BARRON, SEAN C | 1 | 52.9% | +30.9% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17784251 | STABLE ANTI-PD1 ANTIBODY PHARMACEUTICAL FORMULATIONS | PATTERSON, SARAH COOPER | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 16326021 | PROCESS FOR REDUCING UNWANTED CULTURE BYPRODUCTS IN CELL CULTURE MEDIUM | BARRON, SEAN C | 72d overdue |
| 17784251 | STABLE ANTI-PD1 ANTIBODY PHARMACEUTICAL FORMULATIONS | PATTERSON, SARAH COOPER | — |
| 17294030 | STABLE LIQUID COMPOSITION COMPRISING PROTEIN | ALSOMAIRY, SARAH ABDOALATIF | — |
| Art Unit | Apps |
|---|---|
| 1675 | 1 |
| 1646 | 1 |
| 1653 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17784251 | STABLE ANTI-PD1 ANTIBODY PHARMACEUTICAL FORMULATIONS | PATTERSON, SARAH COOPER | 1675 | §103§112 | Non-Final OA | — | Pending | Jun 10, 2022 |
| 17294030 | STABLE LIQUID COMPOSITION COMPRISING PROTEIN | ALSOMAIRY, SARAH ABDOALATIF | 1646 | §103 | Non-Final OA | — | Pending | May 14, 2021 |
| 16326021 | PROCESS FOR REDUCING UNWANTED CULTURE BYPRODUCTS IN CELL CULTURE MEDIUM | BARRON, SEAN C | 1653 | §103 | Final Rejection | 72d overdue | Pending | Mar 13, 2019 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial